{
    "nct_id": "NCT04294264",
    "official_title": "TAS-102 in Combination With Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Histologically confirmed stage IV colon cancer (American Joint Committee on Cancer [AJCC] 7th edition) that has progressed after standard therapy that included fluorouracil (5-FU), irinotecan, oxaliplatin, bevacizumab (unless contraindicated) and an anti-EGFR antibody, if RAS wild type. Patients who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate\n* Patients who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen\n* Progression of disease must be documented on the most recent scan\n* Presence of measurable disease\n* RAS mutation and mismatch repair deficiency (MMR) status must be determined (or tissue availability for testing if not already determined)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Life expectancy of at least 3 months\n* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L\n* Hemoglobin >= 9 g/dL\n* Platelets (PLT) >= 75 x 10^9/L\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN)\n* Adequate contraception if applicable\n* Women who are nursing and discontinue nursing prior to enrollment in the program\n* Ability to take oral medication (i.e., no feeding tube)\n* Patient able and willing to comply with study procedures as per protocol\n* Patient able to understand and willing to sign and date the written voluntary informed consent form (ICF) at screening visit prior to any protocol-specific procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who have previously received TAS-102\n* Grade 2 or higher peripheral neuropathy (functional impairment)\n* Symptomatic central nervous system (CNS) metastases requiring treatment\n* Other active malignancy within the last 3 years (except for non-melanoma skin cancer or a non-invasive/in situ cancer)\n* Pregnancy or breast feeding\n* Current therapy with other investigational agents\n* Active infection with body temperature >= 38 degree Celsius (C) due to infection\n* Major surgery within prior 4 weeks (the surgical incision should be fully healed prior to drug administration)\n* Any anticancer therapy within prior 3 weeks of first dose of study drug\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102\n* Current therapy with other investigational agents or participation in another clinical study or any investigational agent received within prior 4 weeks\n* Grade 3 or higher hypersensitivity reaction to oxaliplatin, or grade 1-2 hypersensitivity reaction to oxaliplatin not controlled with pre-medication\n* Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse (CTCAE) grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum-induced neurotoxicity)",
    "miscellaneous_criteria": ""
}